SOURCE: OmniComm Systems, Inc.

OmniComm Systems, Inc.

December 28, 2015 08:00 ET

OmniComm Systems' TrialMaster® EDC Technology Enables Global Biopharmaceutical Company to Streamline Clinical Development Time and Increase Product Success

FORT LAUDERDALE, FL--(Marketwired - December 28, 2015) - OmniComm Systems, Inc. (OmniComm) (OTCQX: OMCM), a global leading provider of clinical data management technology, today announced the expanded use and adoption of TrialMaster electronic data capture (EDC) by a leading global biopharmaceutical company across its entire pipeline of drug candidates. In 2015 this biopharmaceutical company used TrialMaster to run 23 clinical trials. Since selecting TrialMaster the company has run more than 65 clinical studies across 1,300 investigational sites recruiting more than 3,000 trial volunteers.

TrialMaster was selected, from amongst other electronic data capture systems, for its innovative features and functionality that enabled this biopharmaceutical company to streamline its clinical development timelines and substantially increase the probability of late-stage product success. TrialMaster is being used to support the company's clinical development pipeline across all phases of clinical development, from Phase I through Phase IV, and has fundamentally transformed its entire clinical development process.

"It's been rewarding to be a part of this long term client's rapid growth over the years," said Stephen Johnson, president & chief operating officer at OmniComm. "This year in particular has been a phenomenal year for them and we are proud to be a part of their success. Their commitment to our products and services is greatly appreciated and a testament to TrialMaster and our entire support organization."

Supporting Information

About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world's pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 clinical trials. For more information, visit www.omnicomm.com.

Trademarks
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.